EVALUATION OF IVO COMPOUNDS IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL

To evaluate the efficacy of IVO compounds, the bleomycin-induced pulmonary fibrosis model in C57BL/6J mice, the most well-characterized and widely used preclinical model of IPF, will be used. Bleomycin administration results in reproducible pulmonary inflammation followed by fibrotic remodeling, leading to functional impairments that recapitulate key aspects of human IPF. Project Number: 75N91019D00024-0-759102500022-1 | Fiscal Year: 2025 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: lynn briscoe | Institution: LEIDOS BIOMEDICAL RESEARCH, INC., FREDERICK, MD | Award Amount: $219,752 | Activity Code: N01 View on NIH RePORTER: https://reporter.nih.gov/project-details/11456818